CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
Prior to joining
About
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: risks relating to interests of our largest stockholders that differ from our other stockholders; the difficulty of executing our business strategy in
EVOMELA®, Marqibo® and Zevalin® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.
COMPANY CONTACT: 240.864.2643 |
INVESTOR CONTACT: Solebury Trout 646.378.2962
617.221.9005 |
MEDIA CONTACT: 410.299.3310 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-appointment-of-president-to-its-china-operations-to-lead-commercialization-300722261.html
SOURCE
MLMIC Insurance Company: New York’s Top Medical Liability Insurer Joins Berkshire Hathaway Family of Companies
Symbility becomes the first claims estimating solution on the market to fully integrate with the HOVER platform
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News